SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-000198
Filing Date
2023-01-04
Accepted
2023-01-04 06:22:20
Documents
19
Period of Report
2022-12-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 56627
2 ex4-1.htm EX-4.1 132435
3 ex4-2.htm EX-4.2 110900
4 ex4-3.htm EX-4.3 113645
5 ex5-1.htm EX-5.1 31325
6 ex10-1.htm EX-10.1 239865
7 ex99-1.htm EX-99.1 13208
8 ex5-1_001.jpg GRAPHIC 5516
  Complete submission text file 0001493152-23-000198.txt   1022586

Data Files

Seq Description Document Type Size
9 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gtbp-20221230.xsd EX-101.SCH 3236
10 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gtbp-20221230_lab.xml EX-101.LAB 34240
11 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gtbp-20221230_pre.xml EX-101.PRE 22365
13 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3603
Mailing Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005
Business Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 23504307
SIC: 2834 Pharmaceutical Preparations